Recently, a new antiremodeling therapy (sotatercept), targeting the TGF-β pathway, was demonstrated to improve the hemodynamic and exercise capacity of patients with PAH, opening the way for antiremodeling PAH treatment (3). The gene discussed is TGFB1; the disease is pulmonary arterial hypertension.